Enhertu and Stomach Pain: What Users Say
Reviews for Enhertu
Showing 3 reviews tagged with "stomach pain".
- Pus...
- Taken for less than 1 month
- May 27, 2023
For Breast Cancer, Metastatic "I experienced stomach pain and fatigue during the first week. After week three, my hair started to thin, and my blood count is very low."
- Ano...
- Taken for 1 to 6 months
- August 17, 2025
For Breast Cancer, Metastatic "Hair loss, stomach pain, fatigue, nausea, back pain, constipation, increased hunger, mouth sores. It takes 9-10 days out of the 21-day cycle to recover after each infusion."
Frequently asked questions
- How well does Enhertu work in metastatic breast cancer?
- Is Enhertu a chemotherapy drug? What's Enhertu used for?
See also:
Reviews may be edited to correct grammar/spelling or remove inappropriate content. Reviews appearing to come from parties with a vested interest are not published. This information is not intended to endorse any medication and should not replace the expertise and judgment of healthcare professionals.
More about Enhertu (fam-trastuzumab deruxtecan)
- Enhertu consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (36)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: HER2 inhibitors
- En español
For Stomach Cancer "As a patient, I can't rate the efficacy of this medication because I have had only one round. After many rounds of chemotherapy using other medications, I can say that the side effects of this medication were much worse and enduring after one round. Severe diarrhea, debilitating fatigue, debilitating nausea, and stomach pain. Side effects began on day four and lasted until day 7. Will take half dose next round but will continue on the regimen as prescribed for now. One lousy week out of three is not acceptable to me. If the next round is as bad, I will cease using this medication. The oncologist stated that while I tolerated other regimens better than most, I tolerated Enhertu worse than most."